var data={"title":"Acute bacterial rhinosinusitis in children: Microbiology and treatment","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Acute bacterial rhinosinusitis in children: Microbiology and treatment</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/contributors\" class=\"contributor contributor_credentials\">Ellen R Wald, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/contributors\" class=\"contributor contributor_credentials\">Glenn C Isaacson, MD, FAAP</a></dd><dd><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/contributors\" class=\"contributor contributor_credentials\">Robert A Wood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 30, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute rhinosinusitis is a disease that results from infection of one or more of the paranasal sinuses. A viral infection associated with the common cold is the most frequent etiology of acute rhinosinusitis, more properly called viral rhinosinusitis. (See <a href=\"topic.htm?path=the-common-cold-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;The common cold in children: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=the-common-cold-in-children-management-and-prevention\" class=\"medical medical_review\">&quot;The common cold in children: Management and prevention&quot;</a>.)</p><p>Uncomplicated viral rhinosinusitis usually resolves without treatment in 7 to 10 days. Although untreated acute bacterial rhinosinusitis (ABRS) also may resolve without treatment, treatment with antibiotics hastens recovery [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. It is important to distinguish between uncomplicated viral rhinosinusitis and ABRS to prevent unnecessary use of antibiotics (<a href=\"image.htm?imageKey=PEDS%2F83921\" class=\"graphic graphic_table graphicRef83921 \">table 1</a>).</p><p>The microbiology and treatment of ABRS in children will be discussed here. The clinical features and diagnosis of ABRS in children and acute sinusitis and rhinosinusitis in adults are discussed separately. (See <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=acute-sinusitis-and-rhinosinusitis-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment\" class=\"medical medical_review\">&quot;Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H496645221\"><span class=\"h1\">CLINICAL PRESENTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical presentation of acute bacterial rhinosinusitis in children is characterized by [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3-8\" class=\"abstract_t\">3-8</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Persistent symptoms (nasal discharge or cough or both) for &gt;10 days without improvement, or</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe symptoms (onset with temperature of &ge;39&deg;C [102.2&deg;F] and purulent nasal discharge for &ge;3 consecutive days), or</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Worsening symptoms (respiratory symptoms that worsen after initial improvement) or onset of new fever or severe headache</p><p/><p>(See <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H9\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Acute bacterial rhinosinusitis'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MICROBIOLOGY</span></p><p class=\"headingAnchor\" id=\"H704286561\"><span class=\"h2\">Common pathogens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Haemophilus influenzae</em> (nontypeable), <em>Streptococcus pneumoniae</em>, and <em>Moraxella catarrhalis</em> are the predominant causes of acute bacterial rhinosinusitis (ABRS) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p>Culture of material aspirated from the sinus yielding &ge;10<sup>4</sup> colony-forming <span class=\"nowrap\">units/mL</span> of bacteria is the standard for determining the etiology of ABRS [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/11\" class=\"abstract_t\">11</a>]. However, sinus aspiration is an invasive procedure that is not routinely performed in children with uncomplicated ABRS. Studies of the microbiology of ABRS in which sinus aspirates were obtained from children with uncomplicated ABRS were performed before the widespread development of antibiotic resistant <em>S. pneumoniae</em> [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/5\" class=\"abstract_t\">5</a>]. However, because acute otitis media (AOM) and ABRS have similar pathogenesis and microbiology, data generated from cultures of middle-ear fluid obtained by tympanocentesis from children with AOM can be used as a surrogate for cultures of the paranasal sinuses [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>Although only limited data are available detailing the microbiology of AOM after 2010 (when the seven-valent pneumococcal conjugate vaccine was replaced with the <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-pediatric-drug-information\" class=\"drug drug_pediatric\">13-valent pneumococcal conjugate vaccine</a> [PCV13] in the United States), several publications highlight the prominence of nontypeable <em>H. influenzae</em>, including beta-lactamase positive isolates [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/14-17\" class=\"abstract_t\">14-17</a>]. It is estimated that <em>H. influenzae</em> accounts for approximately 40 to 50 percent, <em>S. pneumoniae</em> for 20 to 25 percent, and <em>M. catarrhalis</em> for 25 percent of middle ear isolates in AOM. It is presumed that isolates recovered from children with ABRS would be similar. (See <a href=\"topic.htm?path=acute-otitis-media-in-children-epidemiology-microbiology-clinical-manifestations-and-complications#H16\" class=\"medical medical_review\">&quot;Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications&quot;, section on 'Microbiology'</a>.)</p><p>Several studies have reported isolation of <em>Staphylococcus aureus</em> from sinus aspirates (obtained endoscopically) or from cultures of the middle meatus in children (most of whom had chronic sinusitis) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/18-20\" class=\"abstract_t\">18-20</a>]. However, these studies must be interpreted with caution because of methodologic limitations (eg, unknown indication for obtaining culture, lack of quantification, and possibility of contamination from the nasal cavity) and because cultures of the middle meatus have not been established as a reliable surrogate for maxillary sinus aspirates in children [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/21\" class=\"abstract_t\">21</a>]. Nonetheless, <em>S. aureus</em> has been recovered from cultures in patients with orbital cellulitis and epidural abscess, presumably complications of ABRS [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/22,23\" class=\"abstract_t\">22,23</a>].</p><p class=\"headingAnchor\" id=\"H704286587\"><span class=\"h2\">Antimicrobial susceptibility</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>S. pneumoniae</em> &ndash; The proportion of isolates of <em>S. pneumoniae</em> that are nonsusceptible to penicillin varies from community to community. Isolates obtained from surveillance centers nationwide indicate that 10 to 15 percent of upper respiratory tract isolates of <em>S. pneumoniae</em> are nonsusceptible to penicillin [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/24,25\" class=\"abstract_t\">24,25</a>]. However, values as high as 50 to 60 percent have been reported in some areas [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/14,15,26,27\" class=\"abstract_t\">14,15,26,27</a>]. Of the organisms that are resistant, approximately one-half are highly resistant to penicillin and the remaining one-half are intermediate in resistance [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/24,25,27-30\" class=\"abstract_t\">24,25,27-30</a>]. The impact of the PCV13 on rates of resistance has been variable. Children unimmunized or underimmunized with PCV are more likely to have resistant strains [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"topic.htm?path=impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states#H10\" class=\"medical medical_review\">&quot;Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States&quot;, section on 'Antibiotic resistance'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>H. influenzae</em> &ndash; Between 10 and 42 percent of <em>H. influenzae</em> [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/14,15,27-30\" class=\"abstract_t\">14,15,27-30</a>] are likely to be beta-lactamase positive and nonsusceptible to <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>M. catarrhalis</em> &ndash; Close to 100 percent of <em>M. catarrhalis</em> are likely to be beta-lactamase positive and nonsusceptible to <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a>.</p><p/><p class=\"headingAnchor\" id=\"H512799123\"><span class=\"h2\">Risks for antimicrobial resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Risks for resistant pathogens include [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4,31-35\" class=\"abstract_t\">4,31-35</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Living in an area with high endemic rates (ie, &ge;10 percent) of invasive penicillin nonsusceptible <em>S. pneumoniae</em></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age &lt;2 years</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Daycare attendance</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibiotic therapy within the past month</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hospitalization within the past five days</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unimmunized or underimmunized with pneumococcal conjugate vaccine</p><p/><p class=\"headingAnchor\" id=\"H742622640\"><span class=\"h1\">INDICATIONS FOR REFERRAL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with uncomplicated acute bacterial rhinosinusitis (ABRS) can usually be managed by their primary care provider. Consultation with a specialist (eg, infectious disease, otolaryngology, immunology) may be warranted in the following circumstances [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4,36,37\" class=\"abstract_t\">4,36,37</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intracranial or orbital complications (<a href=\"image.htm?imageKey=PEDS%2F83408\" class=\"graphic graphic_table graphicRef83408 \">table 2</a>) (see <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H13\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Complications'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Need for sinus aspiration (see <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H495182753\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Microbiologic studies'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Isolation of resistant or rare pathogens from sinus aspirate</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosed or suspected immunodeficiency</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent ABRS, particularly if it exacerbates underlying pulmonary conditions (eg, asthma)</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EMPIRIC ANTIBIOTIC THERAPY</span></p><p class=\"headingAnchor\" id=\"H656460459\"><span class=\"h2\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest that children with a clinical presentation that is compatible with acute bacterial rhinosinusitis (ABRS) (<a href=\"image.htm?imageKey=PEDS%2F103739\" class=\"graphic graphic_table graphicRef103739 \">table 3</a>) be treated with antimicrobial therapy.</p><p>We initiate antimicrobial therapy <strong>at the time of presentation</strong> to medical attention for children with ABRS and [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3\" class=\"abstract_t\">3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A clinical presentation of severe symptoms or worsening symptoms (<a href=\"image.htm?imageKey=PEDS%2F103739\" class=\"graphic graphic_table graphicRef103739 \">table 3</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complications or suspected complications (<a href=\"image.htm?imageKey=PEDS%2F83408\" class=\"graphic graphic_table graphicRef83408 \">table 2</a>) (see <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H13\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Complications'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Receipt of antibiotic therapy in the previous four weeks</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Concurrent bacterial infection (eg, pneumonia, suppurative cervical adenitis, group A streptococcal pharyngitis, acute otitis media)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Certain underlying conditions, including asthma, cystic fibrosis, immunodeficiency, previous sinus surgery, or anatomic abnormalities of the upper respiratory tract</p><p/><p>For children with ABRS and 10 days of symptoms that are neither severe nor worsening (<a href=\"image.htm?imageKey=PEDS%2F103739\" class=\"graphic graphic_table graphicRef103739 \">table 3</a>), we either provide immediate antimicrobial therapy or a three-day period of observation, depending upon patient and family preference. Immediate treatment may shorten the duration of symptoms, but some children may improve without antibiotics. Additional factors that are considered in this decision include severity of symptoms, quality of life, past history of ABRS, cost and ease of administration of antibiotics, and concerns about adverse effects of antibiotics or development of complications.</p><p>Randomized trials evaluating antibiotics versus placebo for the treatment of ABRS in children have conflicting results [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/1,2,38\" class=\"abstract_t\">1,2,38</a>]. In a meta-analysis of three trials including a total of 310 children [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/1,2,38\" class=\"abstract_t\">1,2,38</a>], the rate of improvement or cure was greater among children treated with antibiotics than placebo (78.5 versus 59.7 percent, odds ratio 2.52, 95% CI 1.52-4.18) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>]. In the only study that was performed after the development of widespread antibiotic-resistant <em>S. pneumoniae</em>, treatment with <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> was associated with increased rates of cure (50 versus 14 percent) and decreased rates of treatment failure (14 versus 68 percent) compared with placebo [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/2\" class=\"abstract_t\">2</a>]. Adverse events, predominantly self-limited diarrhea, were more common in the treatment group (44 versus 14 percent), but only three patients in the treatment group discontinued therapy because of adverse effects. Intracranial and intraorbital complications were not observed in the randomized trials, even among the placebo recipients [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. However, too few patients were included to adequately evaluate the risk.</p><p>Unfortunately, there have been no randomized, placebo-controlled trials of antibiotic treatment for ABRS that have used pre- and posttreatment quantitative sinus aspirate culture as the standard for diagnosis and cure. Studies that use clinical <span class=\"nowrap\">and/or</span> radiologic criteria for diagnosis and outcome may underestimate the benefit of antibiotic therapy because they are likely to include at least some patients with self-limited uncomplicated viral upper respiratory tract infection.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Outpatient therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most children with ABRS can be treated as outpatients (<a href=\"image.htm?imageKey=PEDS%2F103996\" class=\"graphic graphic_algorithm graphicRef103996 \">algorithm 1</a>). Those who are toxic-appearing (eg, lethargic, poorly perfused, with cardiorespiratory compromise) or have complications or suspected complications (<a href=\"image.htm?imageKey=PEDS%2F83408\" class=\"graphic graphic_table graphicRef83408 \">table 2</a>) should be admitted for parenteral therapy. (See <a href=\"#H742621521\" class=\"local\">'Inpatient therapy'</a> below.)</p><p>Antibiotics that are used to treat ABRS must provide antibacterial coverage for <em>S. pneumoniae</em>, <em>H. influenzae</em>, and <em>M. catarrhalis</em> (see <a href=\"#H2\" class=\"local\">'Microbiology'</a> above). Additional factors in the choice of therapy include the severity of illness, risk of complications, likelihood of infection with a resistant organism, antimicrobial spectrum, acceptability, dosing convenience, and adverse effects (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4,39\" class=\"abstract_t\">4,39</a>].</p><p>We suggest <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> as the first-line agent for the treatment of ABRS in children because of its spectrum of activity, effectiveness, and safety [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/2,4,40,41\" class=\"abstract_t\">2,4,40,41</a>]. Single-agent alternatives that have a slightly narrower spectrum of activity than amoxicillin-clavulanate include third-generation cephalosporins (eg, <a href=\"topic.htm?path=cefpodoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefpodoxime</a> and <a href=\"topic.htm?path=cefdinir-pediatric-drug-information\" class=\"drug drug_pediatric\">cefdinir</a>) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/42\" class=\"abstract_t\">42</a>]. <a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Levofloxacin</a> may be used when there is no other safe and effective alternative (eg, in patients who have anaphylaxis with or are intolerant of beta-lactams) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/43-45\" class=\"abstract_t\">43-45</a>]. Levofloxacin typically remains active against multi-drug resistant pneumococci with high-level resistance to penicillin or third-generation cephalosporins and is an option for treatment when patients have failed initial therapy. (See <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>.)</p><p class=\"headingAnchor\" id=\"H656458098\"><span class=\"h3\">Mild/moderate disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><span class=\"nowrap\">Mild/moderate</span> ABRS is characterized by 1) temperature &lt;39&deg;C (102.2&deg;F) and lack of systemic signs or 2) a clinical severity score &lt;8 (<a href=\"image.htm?imageKey=PEDS%2F83453\" class=\"graphic graphic_table graphicRef83453 \">table 5</a>).</p><p>For children with uncomplicated <span class=\"nowrap\">mild/moderate</span> ABRS who have no risks for antibiotic resistance, we suggest empiric antimicrobial therapy with standard dose <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> rather than other oral antibiotics (eg, <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a>, fluoroquinolones, macrolides, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a> [TMP-SMX], <a href=\"topic.htm?path=doxycycline-pediatric-drug-information\" class=\"drug drug_pediatric\">doxycycline</a>, or second- or third-generation cephalosporins) (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a>) (see <a href=\"#H512799123\" class=\"local\">'Risks for antimicrobial resistance'</a> above) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">Amoxicillin-clavulanate</a> 45 <span class=\"nowrap\">mg/kg</span> per day of the <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> component orally in two divided doses (maximum daily dose 1.75 g); in the United States, use the 200 or 400 mg <span class=\"nowrap\">amoxicillin/5</span> mL suspension or 200 or 400 mg chewable tablet for the appropriate clavulanate ratio</p><p/><p>For children with uncomplicated <span class=\"nowrap\">mild/moderate</span> ABRS who have one or more risks for antibiotic resistance, we suggest treatment with high-dose rather than standard-dose <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a>) (see <a href=\"#H512799123\" class=\"local\">'Risks for antimicrobial resistance'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">Amoxicillin-clavulanate</a> 90 <span class=\"nowrap\">mg/kg</span> per day of the <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> component orally in two divided doses (maximum daily dose 4 g); in the United States, use the 600 mg <span class=\"nowrap\">amoxicillin/5</span> mL suspension or the 1000 mg extended-release tablet for the appropriate clavulanate ratio</p><p/><p>We suggest <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> rather than <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> because the addition of clavulanate improves coverage for ampicillin-resistant <em>H. influenzae</em> and <em>M. catarrhalis</em>. Beta-lactamase producing nontypeable <em>H. influenzae</em> is an increasingly important cause of respiratory tract infection, particularly in children with acute otitis media (AOM, the microbiology of which is similar to ABRS) since introduction of immunization the <a href=\"topic.htm?path=pneumococcal-conjugate-vaccine-13-valent-pediatric-drug-information\" class=\"drug drug_pediatric\">13-valent pneumococcal conjugate vaccine</a> (PCV13) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4,26,28,41,46-49\" class=\"abstract_t\">4,26,28,41,46-49</a>]. However, some experts suggest that amoxicillin may be used as initial therapy for <span class=\"nowrap\">mild/moderate</span> disease [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3\" class=\"abstract_t\">3</a>]. They recommend amoxicillin 45 <span class=\"nowrap\">mg/kg</span> per day orally divided in two doses for children without risk factors for antimicrobial resistance and amoxicillin 90 <span class=\"nowrap\">mg/kg</span> per day orally divided in two doses for children with risk factors for antimicrobial resistance. (See <a href=\"#H512799123\" class=\"local\">'Risks for antimicrobial resistance'</a> above.)</p><p>High-dose <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> provides better coverage for penicillin nonsusceptible <em>S. pneumoniae</em> and ampicillin-resistant non-beta-lactamase producing <em>H. influenzae</em> than standard dose amoxicillin-clavulanate [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/26,50\" class=\"abstract_t\">26,50</a>]. However, because of the slight increase in cost and side effects, we suggest that high-dose amoxicillin-clavulanate be reserved for children with severe disease or increased or unknown risk of antibiotic resistance (either penicillin-nonsusceptible <em>S. pneumoniae </em>or beta-lactamase producing <em>H. influenzae</em>) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"#H512799123\" class=\"local\">'Risks for antimicrobial resistance'</a> above.)</p><p>In a meta-analysis of randomized trials, fluoroquinolones provided no advantage over beta-lactam antibiotics in the treatment of ABRS in adults [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/51\" class=\"abstract_t\">51</a>]. Although fluoroquinolones have a wider spectrum of activity, they are associated with more severe side effects than <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/44\" class=\"abstract_t\">44</a>]. In vitro studies have demonstrated high rates of resistance among the most common ABRS pathogens to macrolides, TMP-SMX, and variable rates of resistance (especially penicillin nonsusceptible <em>S. pneumoniae</em>) to second- and third-generation cephalosporins [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/26,47,48,52-54\" class=\"abstract_t\">26,47,48,52-54</a>].</p><p class=\"headingAnchor\" id=\"H656458106\"><span class=\"h3\">Severe disease or risk for severe disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Severe disease is characterized by 1) temperature &ge;39&deg;C (102.2&deg;F) or other systemic signs or 2) a clinical severity score &ge;8 (<a href=\"image.htm?imageKey=PEDS%2F83453\" class=\"graphic graphic_table graphicRef83453 \">table 5</a>). Children with immune compromising conditions (eg, human immunodeficiency virus [HIV]) are at increased risk for severe disease [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>].</p><p>For children with severe ABRS or risk for severe ABRS who are treated as outpatients, we suggest treatment with high-dose <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">Amoxicillin-clavulanate</a> 90 <span class=\"nowrap\">mg/kg</span> per day of the <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> component orally in two divided doses (maximum daily dose 4 g); in the United States, use the 600 mg <span class=\"nowrap\">amoxicillin/5</span> mL suspension or the 1000 mg extended-release tablet for the appropriate clavulanate ratio</p><p/><p>We suggest high-dose rather than standard-dose <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> for children with severe ABRS to provide coverage for penicillin-nonsusceptible <em>S. pneumoniae</em> in addition to ampicillin-resistant <em>H. influenzae</em> and <em>M. catarrhalis</em> [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"#H2\" class=\"local\">'Microbiology'</a> above.)</p><p>Alternative single-agent regimens, which have a slightly narrower spectrum of activity than <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a>, include a third-generation cephalosporin such as <a href=\"topic.htm?path=cefpodoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefpodoxime</a> or <a href=\"topic.htm?path=cefdinir-pediatric-drug-information\" class=\"drug drug_pediatric\">cefdinir</a>. Third-generation cephalosporins have been considered less comprehensive because they fall short in covering penicillin-resistant <em>S. pneumoniae</em>. However, if penicillin-resistant <em>S. pneumoniae</em> are diminishing as causes of acute otitis media and acute bacterial sinusitis (since the introduction of immunization with the PCV13) this may be less of an issue (see <a href=\"#H2\" class=\"local\">'Microbiology'</a> above). <a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Levofloxacin</a>, which has a broad spectrum, should be reserved for cases in which there are no alternative choices. Suggested doses are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefpodoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefpodoxime</a> 10 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 hours (maximum daily dose 400 mg),<strong> or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefdinir-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefdinir</a> 14 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 or 24 hours (maximum daily dose 600 mg), <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Levofloxacin</a> 10 to 20 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 to 24 hours (maximum daily dose 500 mg); levofloxacin should be reserved for cases in which there is no other safe and effective alternative [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/43-45\" class=\"abstract_t\">43-45</a>]. (See <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H689793379\"><span class=\"h3\">Penicillin allergy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Alternatives to <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> for children with an allergy to penicillin depend upon the type of allergy (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a>). (See <a href=\"topic.htm?path=penicillin-allergy-immediate-reactions\" class=\"medical medical_review\">&quot;Penicillin allergy: Immediate reactions&quot;</a> and <a href=\"topic.htm?path=allergy-evaluation-for-immediate-penicillin-allergy-skin-test-based-diagnostic-strategies-and-cross-reactivity-with-other-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with uncomplicated ABRS who have a severe type I allergy to penicillin, we suggest <a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">levofloxacin</a> 10 to 20 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 or 24 hours [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4,45\" class=\"abstract_t\">4,45</a>]. (See <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with uncomplicated ABRS who have a non-type I allergy to penicillin, we suggest therapy with a third-generation cephalosporin (eg, <a href=\"topic.htm?path=cefpodoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">cefpodoxime</a> or <a href=\"topic.htm?path=cefdinir-pediatric-drug-information\" class=\"drug drug_pediatric\">cefdinir</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=cefpodoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefpodoxime</a> 10 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 hours (maximum daily dose 400 mg), <strong>or</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=cefdinir-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefdinir</a> 14 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 or 24 hours (maximum daily dose 600 mg)</p><p/><p class=\"headingAnchor\" id=\"H689793371\"><span class=\"h3\">Vomiting</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A single dose of <a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">ceftriaxone</a> 50 <span class=\"nowrap\">mg/kg</span> per day (maximum dose 1 <span class=\"nowrap\">g/day)</span> intravenously or intramuscularly can be used in children with uncomplicated ABRS and vomiting that precludes administration of oral antibiotics [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3,4\" class=\"abstract_t\">3,4</a>]. Therapy with an oral antibiotic should be initiated 24 hours later, provided the vomiting has resolved.</p><p>Vomiting that persists for more than 24 hours and vomiting that is associated with <span class=\"nowrap\">periorbital/orbital</span> swelling <span class=\"nowrap\">and/or</span> persistent headache should prompt consideration of orbital or intracranial complication. Additional evaluation is needed. (See <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H13\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Complications'</a>.)</p><p class=\"headingAnchor\" id=\"H742621521\"><span class=\"h2\">Inpatient therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Indications for hospitalization and parenteral antibiotics include toxic-appearance (eg, lethargic, poorly perfused, cardiorespiratory compromise), complications or suspected complications (<a href=\"image.htm?imageKey=PEDS%2F83408\" class=\"graphic graphic_table graphicRef83408 \">table 2</a>), and treatment failure with outpatient therapy (ie, high-dose <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a>, third-generation cephalosporin, or <a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">levofloxacin</a>). (See <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H13\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Complications'</a> and <a href=\"#H656460010\" class=\"local\">'Treatment failure'</a> below.)</p><p>Sinus imaging with contrast-enhanced computed tomography should be performed in patients with symptoms or signs of intracranial or orbital complications (<a href=\"image.htm?imageKey=PEDS%2F83408\" class=\"graphic graphic_table graphicRef83408 \">table 2</a>). (See <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H13\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Complications'</a>.)</p><p>Consultation with an otolaryngologist for possible sinus aspiration (with Gram stain, aerobic and anaerobic culture, and antimicrobial susceptibility testing) is warranted for children hospitalized with complications or failure of outpatient management [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4,55\" class=\"abstract_t\">4,55</a>]. Endoscopically obtained cultures of the middle meatus are of no use in children suspected to have ABRS because the meatus is colonized with <em>S. pneumoniae</em>, <em>H. influenzae</em>, and <em>M. catarrhalis</em>, even when children are asymptomatic [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/56\" class=\"abstract_t\">56</a>]. Isolation of a pathogen and antimicrobial susceptibilities enable better targeting of antimicrobial therapy. For children who were initially hospitalized for toxic appearance without complications or suspected complications, sinus aspiration may be deferred pending response to intravenous therapy [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H495182753\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Microbiologic studies'</a>.)</p><p>Empiric therapy for children hospitalized with ABRS should provide coverage for highly resistant <em>S. pneumoniae</em> and ampicillin-resistant <em>H. influenzae</em> and <em>M. catarrhalis</em>.<em> </em>The regimen should be adjusted based upon clinical response and culture results.</p><p>For children hospitalized with ABRS, we suggest empiric antibiotic therapy with one of the following regimens (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">Ampicillin-sulbactam</a> 200 to 400 <span class=\"nowrap\">mg/kg</span> per day intravenously (IV) divided every six hours (maximum 8 g <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a> component per day), <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefotaxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefotaxime</a> 100 to 200 <span class=\"nowrap\">mg/kg</span> per day IV divided every six hours (maximum 8 g per day), <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftriaxone</a> 100 <span class=\"nowrap\">mg/kg</span> per day IV divided every 12 hours (maximum 2 g per day), <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Levofloxacin</a> 10 to 20 <span class=\"nowrap\">mg/kg</span> per day IV divided every 12 to 24 hours (maximum 500 mg per day); levofloxacin should be reserved for cases in which there is no other safe and effective alternative [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/43,45\" class=\"abstract_t\">43,45</a>] (see <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>)</p><p/><p>These suggestions are based on in vitro susceptibilities. There are no studies comparing intravenous antibiotic regimens for the treatment of ABRS in children.</p><p class=\"headingAnchor\" id=\"H2529696\"><span class=\"h2\">Complicated sinusitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of complicated sinusitis varies depending upon the complication and is discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Preseptal (periorbital) cellulitis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Orbital cellulitis or orbital subperiosteal abscess (see <a href=\"topic.htm?path=orbital-cellulitis#H24\" class=\"medical medical_review\">&quot;Orbital cellulitis&quot;, section on 'Treatment'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Septic cavernous sinus thrombosis (see <a href=\"topic.htm?path=septic-dural-sinus-thrombosis#H12\" class=\"medical medical_review\">&quot;Septic dural sinus thrombosis&quot;, section on 'Treatment'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Meningitis (see <a href=\"topic.htm?path=bacterial-meningitis-in-children-older-than-one-month-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Bacterial meningitis in children older than one month: Treatment and prognosis&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteomyelitis of the frontal bone associated with a subperiosteal abscess (Pott puffy tumor) (see <a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-management\" class=\"medical medical_review\">&quot;Hematogenous osteomyelitis in children: Management&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intracranial epidural or subdural abscess (see <a href=\"topic.htm?path=spinal-epidural-abscess#H11\" class=\"medical medical_review\">&quot;Spinal epidural abscess&quot;, section on 'Management'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brain abscess (see <a href=\"topic.htm?path=treatment-and-prognosis-of-bacterial-brain-abscess\" class=\"medical medical_review\">&quot;Treatment and prognosis of bacterial brain abscess&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H496645662\"><span class=\"h1\">RESPONSE TO THERAPY</span></p><p class=\"headingAnchor\" id=\"H656460002\"><span class=\"h2\">Improvement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with acute bacterial rhinosinusitis who are treated with an appropriate antimicrobial agent respond within 48 to 72 hours with improvement of symptoms and general well-being [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. We usually continue antimicrobial therapy for total of 10 days in children whose symptoms improve within three days of initial therapy [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"#H9804910\" class=\"local\">'Duration'</a> below.)</p><p class=\"headingAnchor\" id=\"H656460010\"><span class=\"h2\">Treatment failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment failure is defined by worsening within three days or failure to improve after three days of antimicrobial therapy [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Causes of treatment failure may include [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3,4\" class=\"abstract_t\">3,4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Resistant pathogen (see <a href=\"#H2\" class=\"local\">'Microbiology'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complication (<a href=\"image.htm?imageKey=PEDS%2F83408\" class=\"graphic graphic_table graphicRef83408 \">table 2</a>) (see <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H13\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Complications'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Noninfectious etiology (eg, foreign body, structural abnormality) (see <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H21\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Differential diagnosis'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial presentation of immune deficiency [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/58\" class=\"abstract_t\">58</a>] (see <a href=\"topic.htm?path=approach-to-the-child-with-recurrent-infections\" class=\"medical medical_review\">&quot;Approach to the child with recurrent infections&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H1034758001\"><span class=\"h1\">MANAGEMENT OF TREATMENT FAILURE</span></p><p class=\"headingAnchor\" id=\"H656459852\"><span class=\"h2\">In outpatients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For children with uncomplicated acute bacterial rhinosinusitis (ABRS) who are initially treated as outpatients and whose symptoms worsen after two to three days or fail to improve after three days of initial antimicrobial treatment, we suggest broadening antimicrobial coverage or switching to a different class of antibiotic. Potential regimens depend on which antibiotic was used initially and might include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">Amoxicillin-clavulanate</a> 90 <span class=\"nowrap\">mg/kg</span> per day of the <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> component orally in two divided doses (maximum daily dose 4 g; for patients initially treated with low-dose amoxicillin or amoxicillin-clavulanate); in the United States, use the 600 mg <span class=\"nowrap\">amoxicillin/5</span> mL suspension or the 1000 mg extended-release tablet for the appropriate clavulanate ratio</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ceftriaxone-pediatric-drug-information\" class=\"drug drug_pediatric\">Ceftriaxone</a> 50 <span class=\"nowrap\">mg/kg</span> per day intramuscularly for one to three days, followed by <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> 90 <span class=\"nowrap\">mg/kg</span> per day of the <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> component to complete 10 to 14 days (for patients initially treated with low-dose amoxicillin or amoxicillin-clavulanate), <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefpodoxime-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefpodoxime</a> 10 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 hours, <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefdinir-pediatric-drug-information\" class=\"drug drug_pediatric\">Cefdinir</a> 14 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 or 24 hours, <strong>or</strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">Levofloxacin</a> 10 to 20 <span class=\"nowrap\">mg/kg</span> per day orally divided every 12 or 24 hours; levofloxacin should be reserved for cases in which there is no other safe and effective alternative [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/43-45\" class=\"abstract_t\">43-45</a>] (see <a href=\"topic.htm?path=fluoroquinolones#H23\" class=\"medical medical_review\">&quot;Fluoroquinolones&quot;, section on 'Use in children'</a>)</p><p/><p>Imaging <span class=\"nowrap\">and/or</span> sinus aspiration may be indicated to confirm the diagnosis, evaluate complications, and tailor therapy, particularly for children whose symptoms have not improved or have worsened after three days of initial antibiotics and another three days of broadened coverage. (See <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H493278515\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Complicated ABRS'</a> and <a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis#H495182753\" class=\"medical medical_review\">&quot;Acute bacterial rhinosinusitis in children: Clinical features and diagnosis&quot;, section on 'Microbiologic studies'</a>.)</p><p>Hospital admission for a trial of intravenous therapy <span class=\"nowrap\">and/or</span> consultation with a specialist (eg, infectious disease, otolaryngology) may be warranted for children with ABRS who fail to improve after second-line therapy. (See <a href=\"#H742621521\" class=\"local\">'Inpatient therapy'</a> above and <a href=\"#H742622640\" class=\"local\">'Indications for referral'</a> above.)</p><p class=\"headingAnchor\" id=\"H704286720\"><span class=\"h2\">In hospitalized patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Failure to improve or worsening in hospitalized children who are receiving empiric antibiotic therapy warrants additional evaluation, including [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contrast-enhanced computed tomography imaging (or magnetic resonance imaging) to exclude orbital and intracranial complications (if not performed previously)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Quantitative sinus aspirate cultures if they were not obtained at the time of admission</p><p/><p>Antimicrobial therapy should be modified according to results of sinus aspirate cultures as soon as the results are available.</p><p>In an ill child who has not improved despite therapy with a third-generation cephalosporin, <a href=\"topic.htm?path=ampicillin-and-sulbactam-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin-sulbactam</a>, or <a href=\"topic.htm?path=levofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">levofloxacin</a>, if sinus aspirate cultures are unavailable or contraindicated (eg, because the patient is thrombocytopenic) or if no pathogens are isolated, the addition of <a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">vancomycin</a> (to cover highly resistant<em> S. pneumoniae </em>and<em> S. aureus</em>) with or without <a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">metronidazole</a> (to cover anaerobes) may be warranted [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/59\" class=\"abstract_t\">59</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vancomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vancomycin</a> 60 <span class=\"nowrap\">mg/kg</span> per day intravenously (IV) divided every six hours (maximum 4 <span class=\"nowrap\">g/day)</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=metronidazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Metronidazole</a> 30 <span class=\"nowrap\">mg/kg</span> per day IV divided every six hours (maximum 4 <span class=\"nowrap\">g/day)</span></p><p/><p>Consultation with an infectious disease specialist <span class=\"nowrap\">and/or</span> otolaryngologist is suggested.</p><p class=\"headingAnchor\" id=\"H9804910\"><span class=\"h1\">DURATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal duration of therapy for patients with acute bacterial rhinosinusitis (ABRS) has not been studied systematically. We consider 10 days adequate for children whose symptoms improve within three days of initial therapy [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/57\" class=\"abstract_t\">57</a>]. For those who improve more slowly or who have required escalation of therapy, we continue antibiotic therapy for seven days after the patient becomes free of symptoms (ie, a minimum of 10 days) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3,60\" class=\"abstract_t\">3,60</a>]. (See <a href=\"#H496645662\" class=\"local\">'Response to therapy'</a> above.)</p><p>Guidelines from the Infectious Diseases Society of America suggest a 10- to 14-day course for the treatment of ABRS in children [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SYMPTOMATIC TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptomatic management of ABRS is aimed at relief of nasal obstruction and rhinorrhea. Potential symptomatic therapies include saline nasal irrigation, topical or systemic decongestants, antihistamines, intranasal corticosteroids, and sinus aspiration [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3,61-64\" class=\"abstract_t\">3,61-64</a>]. Among these therapies, we prefer saline nose drops <span class=\"nowrap\">and/or</span> saline nasal sprays for children with ABRS. Although efficacy data are limited, the risk of harm is low.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Topical saline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest topical saline as an adjunctive therapy for children with ABRS. Saline nose drops, saline nasal sprays, <span class=\"nowrap\">and/or</span> saline nasal irrigation may help in preventing crust formation and liquefying sinus secretions. In a small randomized trial, nasal saline irrigation improved symptoms, quality of life scores, and peak expiratory flow rates in children with acute sinusitis [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/65\" class=\"abstract_t\">65</a>]. Although the potential benefits for children are not well established by this single trial, topical saline is inexpensive and unlikely to be harmful or impede recovery. It is important that irrigants be prepared from sterile or bottled water; cases of amebic encephalitis associated with nasal irrigation prepared from tap water have been reported [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/66\" class=\"abstract_t\">66</a>]. (See <a href=\"topic.htm?path=free-living-amebas-and-prototheca#H13571662\" class=\"medical medical_review\">&quot;Free-living amebas and Prototheca&quot;, section on 'Epidemiology'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Decongestants and antihistamines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not suggest the use of decongestants or antihistamines in children with ABRS who do not have an underlying allergic component [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3,61\" class=\"abstract_t\">3,61</a>].</p><p>Although decongestants may reduce tissue edema, improve ostial drainage, and provide symptomatic relief [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/61\" class=\"abstract_t\">61</a>], these benefits may be offset by increased viscosity of secretions, decreased blood flow to the nasal mucosa (potentially impeding delivery of antibiotics to the sinuses), and increased irritability in children. Antihistamines also can dry secretions and impair sinus drainage. In a randomized trial in which children with presumed ABRS were treated with <a href=\"topic.htm?path=amoxicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin</a> and a combination decongestant-antihistamine or amoxicillin and placebo, symptoms improved in all children within three days of initiation of antibiotics [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/67\" class=\"abstract_t\">67</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Intranasal corticosteroids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not suggest the use of intranasal corticosteroids in children with ABRS who do not have an underlying allergic component. Although nasal corticosteroids theoretically may decrease inflammation of the mucous membranes, which contributes to obstruction of the ostia and impaired mucociliary clearance [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/68\" class=\"abstract_t\">68</a>], the benefits in randomized trials have been marginal and the trials have methodologic limitations (eg, varying inclusion criteria, inclusion of patients with and without allergies, varying outcome criteria) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3,69-72\" class=\"abstract_t\">3,69-72</a>].</p><p class=\"headingAnchor\" id=\"H656460061\"><span class=\"h2\">Sinus aspiration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sinus aspiration may be warranted for relief of intense headache or facial pain (<a href=\"image.htm?imageKey=PEDS%2F101312\" class=\"graphic graphic_figure graphicRef101312 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/55\" class=\"abstract_t\">55</a>]. Sinus aspiration should be performed by a specialist.</p><p class=\"headingAnchor\" id=\"H3307256762\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-acute-rhinosinusitis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute rhinosinusitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword[s] of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=sinusitis-in-children-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Sinusitis in children (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical presentations compatible with a diagnosis of acute bacterial rhinosinusitis (ABRS) include (see <a href=\"#H496645221\" class=\"local\">'Clinical presentations'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Persistent symptoms (nasal discharge or cough or both) for &gt;10 days without improvement, or</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Severe symptoms (onset with temperature of &ge;39&deg;C [102.2&deg;F] and purulent nasal discharge for &ge;3 consecutive days), or</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Worsening symptoms (respiratory symptoms that worsen or onset of fever or severe headache after initial improvement)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Haemophilus influenzae</em> (nontypeable), <em>Streptococcus pneumoniae</em>, and <em>Moraxella catarrhalis</em> are the predominant causes of uncomplicated ABRS in otherwise healthy children. Approximately 10 to 42 percent of <em>H. influenzae </em>and close to 100 percent of <em>M. catarrhalis</em> respiratory tract isolates are beta-lactamase producing (ie, resistant to <a href=\"topic.htm?path=ampicillin-pediatric-drug-information\" class=\"drug drug_pediatric\">ampicillin</a>). The proportion of <em>S. pneumoniae</em> isolates nonsusceptible to penicillin varies from community to community. Children who are unimmunized or underimmunized with the pneumococcal conjugate vaccine are more likely to have resistant strains. (See <a href=\"#H2\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest that children with a clinical presentation compatible with ABRS (<a href=\"image.htm?imageKey=PEDS%2F103739\" class=\"graphic graphic_table graphicRef103739 \">table 3</a>)be treated with antimicrobial therapy (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). For most children with ABRS, we initiate antimicrobial therapy at the time of presentation to medical attention. However, for children with ABRS and 10 days of symptoms that are neither severe nor worsening (<a href=\"image.htm?imageKey=PEDS%2F103739\" class=\"graphic graphic_table graphicRef103739 \">table 3</a>), we either provide immediate antimicrobial therapy or a three-day period of observation, depending upon patient and family preference. (See <a href=\"#H656460459\" class=\"local\">'General principles'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most children with ABRS can be treated as outpatients (<a href=\"image.htm?imageKey=PEDS%2F103996\" class=\"graphic graphic_algorithm graphicRef103996 \">algorithm 1</a>). Those who have toxic-appearance (eg, lethargy, poor perfusion, cardiorespiratory compromise), or complications or suspected complications (<a href=\"image.htm?imageKey=PEDS%2F83408\" class=\"graphic graphic_table graphicRef83408 \">table 2</a>) generally should be admitted for parenteral therapy. (See <a href=\"#H6\" class=\"local\">'Outpatient therapy'</a> above and <a href=\"#H742621521\" class=\"local\">'Inpatient therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The choice of antibiotic is based upon the degree of severity of illness, recent exposure to antibiotics, and the likelihood of infection with resistant bacteria (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a> and <a href=\"image.htm?imageKey=PEDS%2F103996\" class=\"graphic graphic_algorithm graphicRef103996 \">algorithm 1</a>). We suggest <a href=\"topic.htm?path=amoxicillin-and-clavulanate-pediatric-drug-information\" class=\"drug drug_pediatric\">amoxicillin-clavulanate</a> rather than other oral antibiotics as the initial treatment for uncomplicated ABRS in children (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H6\" class=\"local\">'Outpatient therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment failure is defined by worsening after two to three days or failure to improve after three days of antimicrobial therapy. Causes of treatment failure may include a resistant pathogen, complication, noninfectious etiology (eg, foreign body), or immune deficiency. (See <a href=\"#H656460010\" class=\"local\">'Treatment failure'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with uncomplicated ABRS who are initially treated as outpatients and whose symptoms worsen after two to three days or fail to improve after three days, we broaden antimicrobial coverage or switch to a different class of antibiotic (<a href=\"image.htm?imageKey=PEDS%2F83454\" class=\"graphic graphic_table graphicRef83454 \">table 4</a>). (See <a href=\"#H656459852\" class=\"local\">'In outpatients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We continue antibiotics for 10 days in children whose symptoms improve within three days of initial therapy. For children who respond more slowly, we continue antibiotics for seven days after symptoms resolve (a minimum of 10 days). (See <a href=\"#H9804910\" class=\"local\">'Duration'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest saline nose drops <span class=\"nowrap\">and/or</span> saline nasal sprays for children with ABRS (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We suggest not using decongestants, antihistamines, or nasal corticosteroids (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H11\" class=\"local\">'Symptomatic treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/1\" class=\"nounderline abstract_t\">Wald ER, Chiponis D, Ledesma-Medina J. Comparative effectiveness of amoxicillin and amoxicillin-clavulanate potassium in acute paranasal sinus infections in children: a double-blind, placebo-controlled trial. Pediatrics 1986; 77:795.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/2\" class=\"nounderline abstract_t\">Wald ER, Nash D, Eickhoff J. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics 2009; 124:9.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/3\" class=\"nounderline abstract_t\">Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics 2013; 132:e262.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/4\" class=\"nounderline abstract_t\">Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54:e72.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/5\" class=\"nounderline abstract_t\">Wald ER, Milmoe GJ, Bowen A, et al. Acute maxillary sinusitis in children. N Engl J Med 1981; 304:749.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/6\" class=\"nounderline abstract_t\">Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 2004; 114:155.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/7\" class=\"nounderline abstract_t\">Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Developing guidance for clinical trials. Otolaryngol Head Neck Surg 2006; 135:S31.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/8\" class=\"nounderline abstract_t\">Thomas M, Yawn BP, Price D, et al. EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 - a summary. Prim Care Respir J 2008; 17:79.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/9\" class=\"nounderline abstract_t\">Gwaltney JM Jr, Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992; 90:457.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/10\" class=\"nounderline abstract_t\">Wald ER. Microbiology of acute and chronic sinusitis in children and adults. Am J Med Sci 1998; 316:13.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/11\" class=\"nounderline abstract_t\">Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol 2014; 113:347.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/12\" class=\"nounderline abstract_t\">Parsons DS, Wald ER. Otitis media and sinusitis: similar diseases. Otolaryngol Clin North Am 1996; 29:11.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/13\" class=\"nounderline abstract_t\">Marchisio P, Ghisalberti E, Fusi M, et al. Paranasal sinuses and middle ear infections: what do they have in common? Pediatr Allergy Immunol 2007; 18 Suppl 18:31.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/14\" class=\"nounderline abstract_t\">Kaur R, Casey JR, Pichichero ME. Relationship with original pathogen in recurrence of acute otitis media after completion of amoxicillin/clavulanate: bacterial relapse or new pathogen. Pediatr Infect Dis J 2013; 32:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/15\" class=\"nounderline abstract_t\">Pichichero ME. Otitis media. Pediatr Clin North Am 2013; 60:391.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/16\" class=\"nounderline abstract_t\">van Dongen TM, van der Heijden GJ, Venekamp RP, et al. A trial of treatment for acute otorrhea in children with tympanostomy tubes. N Engl J Med 2014; 370:723.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/17\" class=\"nounderline abstract_t\">Kaur R, Czup K, Casey JR, Pichichero ME. Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. BMC Infect Dis 2014; 14:640.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/18\" class=\"nounderline abstract_t\">Whitby CR, Kaplan SL, Mason EO Jr, et al. Staphylococcus aureus sinus infections in children. Int J Pediatr Otorhinolaryngol 2011; 75:118.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/19\" class=\"nounderline abstract_t\">Huang WH, Hung PK. Methicillin-resistant Staphylococcus aureus infections in acute rhinosinusitis. Laryngoscope 2006; 116:288.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/20\" class=\"nounderline abstract_t\">Payne SC, Benninger MS. Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a meta-analysis. Clin Infect Dis 2007; 45:e121.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/21\" class=\"nounderline abstract_t\">Wald ER. Staphylococcus aureus: is it a pathogen of acute bacterial sinusitis in children and adults? Clin Infect Dis 2012; 54:826.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/22\" class=\"nounderline abstract_t\">Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/23\" class=\"nounderline abstract_t\">Goytia VK, Giannoni CM, Edwards MS. Intraorbital and intracranial extension of sinusitis: comparative morbidity. J Pediatr 2011; 158:486.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/24\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae--United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2008; 57:1353.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. 2011. Available at: www.cdc.gov/abcs/reports-findings/survreports/spneu09.html (Accessed on April 23, 2012).</li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/26\" class=\"nounderline abstract_t\">Harrison CJ, Woods C, Stout G, et al. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009; 63:511.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/27\" class=\"nounderline abstract_t\">Garbutt J, St Geme JW 3rd, May A, et al. Developing community-specific recommendations for first-line treatment of acute otitis media: is high-dose amoxicillin necessary? Pediatrics 2004; 114:342.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/28\" class=\"nounderline abstract_t\">Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007; 20:368.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/29\" class=\"nounderline abstract_t\">Critchley IA, Jacobs MR, Brown SD, et al. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem. Antimicrob Agents Chemother 2008; 52:2639.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/30\" class=\"nounderline abstract_t\">Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010; 54:2716.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/31\" class=\"nounderline abstract_t\">Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15 Suppl 3:16.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/32\" class=\"nounderline abstract_t\">Wald ER, Mason EO Jr, Bradley JS, et al. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997. Pediatr Infect Dis J 2001; 20:34.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/33\" class=\"nounderline abstract_t\">Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Toronto Child Care Centre Study Group. Arch Pediatr Adolesc Med 1999; 153:495.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/34\" class=\"nounderline abstract_t\">Chung A, Perera R, Brueggemann AB, et al. Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ 2007; 335:429.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/35\" class=\"nounderline abstract_t\">Wald ER, Dashefsky B, Byers C, et al. Frequency and severity of infections in day care. J Pediatr 1988; 112:540.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/36\" class=\"nounderline abstract_t\">Blomgren K, Alho OP, Ertama L, et al. Acute sinusitis: Finnish clinical practice guidelines. Scand J Infect Dis 2005; 37:245.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/37\" class=\"nounderline abstract_t\">Manning SC. Pediatric sinusitis. Otolaryngol Clin North Am 1993; 26:623.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/38\" class=\"nounderline abstract_t\">Garbutt JM, Goldstein M, Gellman E, et al. A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis. Pediatrics 2001; 107:619.</a></li><li class=\"breakAll\">Cherry JD, Kuan EC, Shapiro NL. Rhinosinusitis. In: Feigin and Cherry&rsquo;s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry JD, Harrison G, Kaplan SL, et al (Eds), Elsevier, Philadelphia 2018. p.137.</li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/40\" class=\"nounderline abstract_t\">Ip S, Fu L, Balk E, et al. Update on acute bacterial rhinosinusitis. Evid Rep Technol Assess (Summ) 2005; :1.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/41\" class=\"nounderline abstract_t\">Wald ER, DeMuri GP. Commentary: antibiotic recommendations for acute otitis media and acute bacterial sinusitis in 2013--the conundrum. Pediatr Infect Dis J 2013; 32:641.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/42\" class=\"nounderline abstract_t\">DeMuri GP, Wald ER. Clinical practice. Acute bacterial sinusitis in children. N Engl J Med 2012; 367:1128.</a></li><li class=\"breakAll\">US Food and Drug Administration. FDA Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 13, 2016).</li><li class=\"breakAll\">United States Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm (Accessed on July 28, 2016).</li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/45\" class=\"nounderline abstract_t\">Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/46\" class=\"nounderline abstract_t\">Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010; 29:304.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/47\" class=\"nounderline abstract_t\">Critchley IA, Brown SD, Traczewski MM, et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother 2007; 51:4382.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/48\" class=\"nounderline abstract_t\">Sahm DF, Brown NP, Draghi DC, et al. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. Postgrad Med 2008; 120:8.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/49\" class=\"nounderline abstract_t\">Casey JR, Kaur R, Friedel VC, Pichichero ME. Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York. Pediatr Infect Dis J 2013; 32:805.</a></li><li class=\"breakAll\">IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults. http://www.idsociety.org/IDSA_Practice_Guidelines/ (Accessed on June 24, 2016).</li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/51\" class=\"nounderline abstract_t\">Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, et al. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008; 178:845.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/52\" class=\"nounderline abstract_t\">Fenoll A, Gim&eacute;nez MJ, Robledo O, et al. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin. J Chemother 2008; 20:175.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/53\" class=\"nounderline abstract_t\">Sader HS, Jacobs MR, Fritsche TR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis 2007; 57:5S.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/54\" class=\"nounderline abstract_t\">Jansen WT, Verel A, Beitsma M, et al. Surveillance study of the susceptibility of Haemophilus influenzae to various antibacterial agents in Europe and Canada. Curr Med Res Opin 2008; 24:2853.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/55\" class=\"nounderline abstract_t\">Wald ER, Reilly JS, Casselbrant M, et al. Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor. J Pediatr 1984; 104:297.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/56\" class=\"nounderline abstract_t\">Gordts F, Abu Nasser I, Clement PA, et al. Bacteriology of the middle meatus in children. Int J Pediatr Otorhinolaryngol 1999; 48:163.</a></li><li class=\"breakAll\">Wald ER, DeMuri GP. Sinusitis. In: Principles and Practice of Pediatric Infectious Diseases, 5th ed, Long SS, Prober CG, Fischer M (Eds), Elsevier, Philadelphia 2018. p.230.</li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/58\" class=\"nounderline abstract_t\">Shapiro GG, Virant FS, Furukawa CT, et al. Immunologic defects in patients with refractory sinusitis. Pediatrics 1991; 87:311.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/59\" class=\"nounderline abstract_t\">Wald ER. Microbiology of acute and chronic sinusitis in children. J Allergy Clin Immunol 1992; 90:452.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/60\" class=\"nounderline abstract_t\">Wald ER. Sinusitis. Pediatr Ann 1998; 27:811.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/61\" class=\"nounderline abstract_t\">Leung AK, Kellner JD. Acute sinusitis in children: diagnosis and management. J Pediatr Health Care 2004; 18:72.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/62\" class=\"nounderline abstract_t\">Ioannidis JP, Lau J. Technical report: evidence for the diagnosis and treatment of acute uncomplicated sinusitis in children: a systematic overview. Pediatrics 2001; 108:E57.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/63\" class=\"nounderline abstract_t\">Novembre E, Mori F, Pucci N, et al. Systemic treatment of rhinosinusitis in children. Pediatr Allergy Immunol 2007; 18 Suppl 18:56.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/64\" class=\"nounderline abstract_t\">Shaikh N, Wald ER. Decongestants, antihistamines and nasal irrigation for acute sinusitis in children. Cochrane Database Syst Rev 2014; :CD007909.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/65\" class=\"nounderline abstract_t\">Wang YH, Yang CP, Ku MS, et al. Efficacy of nasal irrigation in the treatment of acute sinusitis in children. Int J Pediatr Otorhinolaryngol 2009; 73:1696.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/66\" class=\"nounderline abstract_t\">Yoder JS, Straif-Bourgeois S, Roy SL, et al. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin Infect Dis 2012; 55:e79.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/67\" class=\"nounderline abstract_t\">McCormick DP, John SD, Swischuk LE, Uchida T. A double-blind, placebo-controlled trial of decongestant-antihistamine for the treatment of sinusitis in children. Clin Pediatr (Phila) 1996; 35:457.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/68\" class=\"nounderline abstract_t\">Patow CA, Kaliner M. Corticosteroid treatment of rhinologic diseases. Ear Nose Throat J 1983; 62:14.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/69\" class=\"nounderline abstract_t\">Barlan IB, Erkan E, Bakir M, et al. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol 1997; 78:598.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/70\" class=\"nounderline abstract_t\">Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol 1993; 92:812.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/71\" class=\"nounderline abstract_t\">Yilmaz G, Varan B, Yilmaz T, G&uuml;rakan B. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Eur Arch Otorhinolaryngol 2000; 257:256.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-bacterial-rhinosinusitis-in-children-microbiology-and-treatment/abstract/72\" class=\"nounderline abstract_t\">Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev 2013; :CD005149.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5999 Version 35.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H496645221\" id=\"outline-link-H496645221\">CLINICAL PRESENTATIONS</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MICROBIOLOGY</a><ul><li><a href=\"#H704286561\" id=\"outline-link-H704286561\">Common pathogens</a></li><li><a href=\"#H704286587\" id=\"outline-link-H704286587\">Antimicrobial susceptibility</a></li><li><a href=\"#H512799123\" id=\"outline-link-H512799123\">Risks for antimicrobial resistance</a></li></ul></li><li><a href=\"#H742622640\" id=\"outline-link-H742622640\">INDICATIONS FOR REFERRAL</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EMPIRIC ANTIBIOTIC THERAPY</a><ul><li><a href=\"#H656460459\" id=\"outline-link-H656460459\">General principles</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Outpatient therapy</a><ul><li><a href=\"#H656458098\" id=\"outline-link-H656458098\">- Mild/moderate disease</a></li><li><a href=\"#H656458106\" id=\"outline-link-H656458106\">- Severe disease or risk for severe disease</a></li><li><a href=\"#H689793379\" id=\"outline-link-H689793379\">- Penicillin allergy</a></li><li><a href=\"#H689793371\" id=\"outline-link-H689793371\">- Vomiting</a></li></ul></li><li><a href=\"#H742621521\" id=\"outline-link-H742621521\">Inpatient therapy</a></li><li><a href=\"#H2529696\" id=\"outline-link-H2529696\">Complicated sinusitis</a></li></ul></li><li><a href=\"#H496645662\" id=\"outline-link-H496645662\">RESPONSE TO THERAPY</a><ul><li><a href=\"#H656460002\" id=\"outline-link-H656460002\">Improvement</a></li><li><a href=\"#H656460010\" id=\"outline-link-H656460010\">Treatment failure</a></li></ul></li><li><a href=\"#H1034758001\" id=\"outline-link-H1034758001\">MANAGEMENT OF TREATMENT FAILURE</a><ul><li><a href=\"#H656459852\" id=\"outline-link-H656459852\">In outpatients</a></li><li><a href=\"#H704286720\" id=\"outline-link-H704286720\">In hospitalized patients</a></li></ul></li><li><a href=\"#H9804910\" id=\"outline-link-H9804910\">DURATION</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">SYMPTOMATIC TREATMENT</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Topical saline</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Decongestants and antihistamines</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Intranasal corticosteroids</a></li><li><a href=\"#H656460061\" id=\"outline-link-H656460061\">Sinus aspiration</a></li></ul></li><li><a href=\"#H3307256762\" id=\"outline-link-H3307256762\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H24597595\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/5999|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/103996\" class=\"graphic graphic_algorithm\">- Outpatient treatment of ABRS in children</a></li></ul></li><li><div id=\"PEDS/5999|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/101312\" class=\"graphic graphic_figure\">- Sinusitis antral puncture</a></li></ul></li><li><div id=\"PEDS/5999|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/83921\" class=\"graphic graphic_table\">- Viral versus bacterial sinusitis</a></li><li><a href=\"image.htm?imageKey=PEDS/83408\" class=\"graphic graphic_table\">- Complications sinusitis children</a></li><li><a href=\"image.htm?imageKey=PEDS/103739\" class=\"graphic graphic_table\">- Clinical presentations ABRS children</a></li><li><a href=\"image.htm?imageKey=PEDS/83454\" class=\"graphic graphic_table\">- Antimicrobial regimens sinusitis children</a></li><li><a href=\"image.htm?imageKey=PEDS/83453\" class=\"graphic graphic_table\">- Sinusitis clinical severity score</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-bacterial-rhinosinusitis-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">Acute bacterial rhinosinusitis in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-otitis-media-in-children-epidemiology-microbiology-clinical-manifestations-and-complications\" class=\"medical medical_review\">Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-sinusitis-and-rhinosinusitis-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=allergy-evaluation-for-immediate-penicillin-allergy-skin-test-based-diagnostic-strategies-and-cross-reactivity-with-other-beta-lactam-antibiotics\" class=\"medical medical_review\">Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-child-with-recurrent-infections\" class=\"medical medical_review\">Approach to the child with recurrent infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bacterial-meningitis-in-children-older-than-one-month-treatment-and-prognosis\" class=\"medical medical_review\">Bacterial meningitis in children older than one month: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluoroquinolones\" class=\"medical medical_review\">Fluoroquinolones</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=free-living-amebas-and-prototheca\" class=\"medical medical_review\">Free-living amebas and Prototheca</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematogenous-osteomyelitis-in-children-management\" class=\"medical medical_review\">Hematogenous osteomyelitis in children: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=impact-of-universal-infant-immunization-with-pneumococcal-streptococcus-pneumoniae-conjugate-vaccines-in-the-united-states\" class=\"medical medical_review\">Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=orbital-cellulitis\" class=\"medical medical_review\">Orbital cellulitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sinusitis-in-children-the-basics\" class=\"medical medical_basics\">Patient education: Sinusitis in children (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=penicillin-allergy-immediate-reactions\" class=\"medical medical_review\">Penicillin allergy: Immediate reactions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=septic-dural-sinus-thrombosis\" class=\"medical medical_review\">Septic dural sinus thrombosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-rhinosinusitis\" class=\"medical medical_society_guidelines\">Society guideline links: Acute rhinosinusitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=spinal-epidural-abscess\" class=\"medical medical_review\">Spinal epidural abscess</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-common-cold-in-children-clinical-features-and-diagnosis\" class=\"medical medical_review\">The common cold in children: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-common-cold-in-children-management-and-prevention\" class=\"medical medical_review\">The common cold in children: Management and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-bacterial-brain-abscess\" class=\"medical medical_review\">Treatment and prognosis of bacterial brain abscess</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment\" class=\"medical medical_review\">Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment</a></li></ul></div></div>","javascript":null}